Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-08

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to evaluate the efficacy of the Premium Scalp Revitalizing Essence on human scalp skin. A total of 60 healthy adults, aged 18 to 60, will be recruited and randomly assigned into five groups receiving different formulations. Participants will use the product once daily for 56 days, and their scalp conditions will be assessed through skin texture tests at multiple time points. Key parameters such as sebum content, overall hair loss, hair density, scalp condition, and hair length will be measured.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir

NCT07271212

Scalp Health Hair Condition Hair Loss +4 more

ACTIVE_NOT_RECRUITING NA

Impact of a Topical Cosmetic Product on Women's Hair

NCT06060834

Hair Thinning Hair Loss

COMPLETED NA

Effectiveness of a Novel Dietary Ingredient on Hair Growth and Skin's Appearance

NCT06010745

Hair Thinning Facial Skin Texture Skin Ageing

UNKNOWN NA

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

NCT01451112

Androgenetic Alopecia Male Pattern Baldness Female Pattern Baldness

COMPLETED PHASE2

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

NCT01451138

Androgenetic Alopecia Male Pattern Baldness Female Pattern Baldness

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, double-blinded, and placebo-controlled study to investigate the effects of Premium Scalp Revitalizing Essence on changes in the skin texture of human scalp skin.

Sixty healthy adults aged from 18 to 60 will be recruited and randomly assigned into five groups, with 12 individuals in each group. Group 1 uses Placebo (Base formula without caffeine and panthenol); Group 2 uses the Base formula (Control with caffeine and panthenol); Group 3 uses Base + IGF-1 \& FGF-7; Group 4 uses Base + Centella asiatica extracellular vesicles; Group 5 uses Base + Centella Asiatica Exosome + IGF-1 \& FGF-7. Before using the test product, all 60 participants undergo the first scalp skin texture test. After 14 days of using the test product, a second scalp skin texture test is conducted; after 28 days of use, a third test is performed; after 42 days of use, a fourth test is conducted; and after 56 days of use, a fifth test is carried out. The scalp skin texture tests include measurements of skin (1) sebum content, (2) overall hair loss, (3) hair density, (4) scalp condition, (5) hair length, and other parameters. The Sebumeter® SM815 probe of the MPA580 device and the ScalpX Intelligent Scalp Diagnostic System will be used to measure the parameters of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scalp Health Hair Condition Hair Loss Sebum Production Hair and Scalp Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Placebo control

Base formula without caffeine and panthenol

Group Type PLACEBO_COMPARATOR

Placebo control

Intervention Type OTHER

Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Group 2: Base formula only

Base formula consisting of active ingredients caffeine and panthenol (vitamin B5).

Group Type EXPERIMENTAL

Base formula only

Intervention Type OTHER

Base formula consisting of active ingredients caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Group 3: Base formula plus IGF-1 & FGF-7.

Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7)

Group Type EXPERIMENTAL

Base formula plus IGF-1 and FGF-7

Intervention Type OTHER

Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Base formula plus Centella asiatica extracellular vesicles

Group Type EXPERIMENTAL

Base formula plus Centella asiatica extracellular vesicles

Intervention Type OTHER

Base formula plus Centella asiatica extracellular vesicles. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Group 5: Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7.

Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7).

Group Type EXPERIMENTAL

Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7

Intervention Type OTHER

Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo control

Placebo control (base formula without caffeine and panthenol). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Intervention Type OTHER

Base formula only

Base formula consisting of active ingredients caffeine and panthenol. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Intervention Type OTHER

Base formula plus IGF-1 and FGF-7

Base formula plus insulin growth factor 1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Intervention Type OTHER

Base formula plus Centella asiatica extracellular vesicles

Base formula plus Centella asiatica extracellular vesicles. Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Intervention Type OTHER

Base formula plus Centella asiatica extracellular vesicles, IGF-1 & FGF-7

Base formula plus Centella asiatica extracellular vesicles, insulin growth factor-1 (IGF-1) and fibroblast growth factor-7 (FGF-7). Applied 1mL evenly to the scalp once daily after hair wash for 56 consecutive days.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults of any gender from the age of 18 to 60 years (inclusive).
* Absence of chronic diseases, major illnesses, or allergies.
* Major illnesses include cancer, post-stroke disorders, paralysis, acute myocardial infarction, coro-nary artery bypass surgery, end-stage renal disease, and major organ transplant or hematopoietic stem cell transplant